-
11.18.2020 | CARB-X is funding Clarametyx Biosciences to develop an innovative immune-enabling antibody therapy targeting serious biofilm-associated infections
CARB-X is awarding up to US$2.42 million to Clarametyx Biosciences to develop a new treatment for serious bacterial biofilm infections, including those such as pneumonia caused by antibiotic-resistant ESKAPE pathogens and polymicrobial biofilms.
-
11.10.2020 | CARB-X is funding Locus Biosciences to develop an innovative CRISPR Cas-3-enhanced bacteriophage targeting antibiotic-resistant Klebsiella pneumoniae infections
CARB-X is awarding up to US$2.05 million to Locus Biosciences to develop a new precision medicine to treat serious recurring urinary tract infections (rUTI) caused by the bacterial pathogen Klebsiella pneumoniae.
-
10.21.2020 | CARB-X is funding Cellics Therapeutics to develop a novel macrophage nanosponge to prevent and treat sepsis
CARB-X is awarding up to US$3.94 million to Cellics Therapeutics, based in San Diego, CA, USA, to develop a new treatment for sepsis caused by drug-resistant Gram-positive and Gram-negative bacteria.
-
10.20.2020 | CARB-X 2019-20 Annual Report: Record high awards and funding during its fiscal year in the race against drug-resistant bacteria
CARB-X closed out its 2019-20 fiscal year with a record number of awards and a list of solid achievements, ramping up its efforts to accelerate innovation to combat the spread of antibiotic resistant bacteria. During the fiscal year which ended July 31, 2020, CARB-X granted $127.5 million to product developers and issued 23 new awards to support the early development of novel antibacterial products – the highest number of new awards in any single year since CARB-X was launched in 2016. The achievement is just one of the highlights in CARB-X’s 2019-2020 Annual Report published today.
-
10.14.2020 | CARB-X is funding Polyphor to develop a new antibiotic to treat multidrug-resistant Enterobacteriaceae Gram-negative bacterial infections
CARB-X is awarding up to US$2.62 million to Polyphor AG (SIX:POLN), headquartered in Allschwil, Switzerland, to develop a new antibiotic to treat serious Enterobacteriaceae Gram-negative bacterial infections, including those caused by life-threatening carbapenem-resistant Enterobacteriaceae (CRE).
-
10.04.2020 | CARB-X is funding GangaGen Biotechnologies to develop a new drug to treat pneumonia caused by multidrug-resistant Klebsiella pneumoniae bacteria
CARB-X is awarding up to US$2.5 million to GangaGen Biotechnologies to develop novel antibacterial proteins, called klebicins, to treat pneumonia caused by Klebsiella pneumoniae.
-
09.22.2020 | CARB-X funds GSK to develop a new drug for urinary tract infections (UTI) caused by Escherichia coli bacteria
CARB-X is awarding up to US$7.51 million to GlaxoSmithKline (NYSE: GSK), to develop a new drug to treat and prevent recurrent urinary tract infections (UTIs) caused by the Escherichia coli (E. coli) bacteria.
-
08.11.2020 | CARB-X is funding Evotec to develop a new class of broad-spectrum antibiotics to treat multidrug-resistant bacterial infections
CARB-X is awarding up to US$2.91 million to Evotec SE, a drug discovery and development company headquartered in Hamburg, Germany, to develop a new class of antibiotics to treat infections caused by deadly multidrug-resistant Gram-positive and Gram-negative bacteria. Evotec will be eligible for an additional $5.53 million in non-dilutive funding from CARB-X if project milestones are met, subject to available funds.
-
07.07.2020 | CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent infections that cause life-threatening pneumonia and other deadly infections
CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia.
-
06.30.2020 | CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics derived from bacteriophages to kill superbugs and prevent deadly infections in transplant patients
CARB-X is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05 million if project milestones are met, for the development of a new generation of highly-specific antimicrobials to prevent multi-drug-resistant bacterial infections in organ transplant patients.
-
06.22.2020 | CARB-X funds University of Queensland to accelerate the development of a new class of last-resort antibiotics to treat deadly superbug infections
CARB-X is awarding up to US$3.83 million to The University of Queensland’s Institute for Molecular Bioscience, Brisbane, Australia, to develop a new class of antibiotics to treat serious drug-resistant bacterial infections
-
06.22.2020 | CARB-X expands awards to Amicrobe by $4.6M to accelerate development of two distinct Amicidin-β topical antimicrobial products
CARB-X is awarding US$4.6M to Amicrobe Inc. to expand development of its bioengineered Amicidin-β synthetic protein designed to kill bacteria and cleanse tissues
-
06.17.2020 | CARB-X funds Module Innovations to develop a simple test to diagnose urinary tract infections (UTI) and identify superbugs causing the infection within 2 hours
CARB-X is awarding Module Innovations of Pune, India, up to US$702,000 plus up to $2.5 million more if certain project milestones are met, to develop a rapid diagnostic for drug-resistant urinary tract infections (UTI) infections.
-
05.28.2020 | CARB-X funds Microbion to develop inhaled drug to treat cystic fibrosis-related lung infections
CARB-X is awarding Microbion Corporation of Bozeman, MT, USA, up to $6.1 million plus up to $5.4 million more if certain project milestones are met, to develop its anti-infective drug pravibismane for the treatment of cystic fibrosis (CF)-related pulmonary infections.
-
05.18.2020 | CARB-X funds Facile Therapeutics to develop a new treatment to prevent recurring C. difficile bacterial infections
CARB-X is awarding Facile Therapeutics, based in Belmont, California, USA, up to $1.26 million to develop a new orally bioavailable drug to treat recurring infections caused by Clostridium difficile. Facile could receive up to $17 million more in additional funding from CARB-X if the project achieves certain development milestones, for a potential total of $18.26 million.
-
05.11.2020 | CARB-X funds 60th project – $220M invested so far, plus millions more if milestones are met
CARB-X announced its 60th award today, representing more than $220 million invested since CARB-X was established in 2016 to support the early development of innovative products to fight drug resistance.
-
05.11.2020 | CARB-X awards Day Zero Diagnostics $6.2M to develop a new test that would diagnose deadly superbug infections faster and determine what antibiotic would be most effective
CARB-X is awarding Day Zero Diagnostics, based in Boston, up to US$6.2 million in non-dilutive funding to develop a diagnostic system that could diagnose bacterial infections more quickly – within hours rather than days - and show physicians which antibiotics are most likely to effectively treat the infection. The innovative technology combines whole-genome sequencing and machine learning to identify the species of a pathogen and its drug-resistance profile without the need for culture, providing physicians with vital information to speed the appropriate treatment of serious drug-resistant bacterial infections in hours rather than days.
-
03.17.2020 | CARB-X funds Microbiotix to develop a novel oral antibiotic to treat multidrug-resistant gonorrhea
CARB-X is awarding Microbiotix, a US-based clinical-stage biopharmaceutical company in Worcester, MA, up to US$2.86 million in non-dilutive funding to develop a new oral antibiotic to treat multidrug-resistant gonorrhea, a sexually transmitted disease caused by bacteria that have developed resistance to all but one existing antibiotic. If the project successfully achieves certain development milestones, Microbiotix will be eligible for an additional $16 million in funding from CARB-X.
-
02.25.2020 | CARB-X funds Peptilogics to develop a new class of antibiotics to treat serious superbug infections associated with implants
CARB-X is awarding Peptilogics, headquartered in Pittsburgh, USA, up to US$2.56 million in non-dilutive funding to develop a new class of peptide antibiotics with broad activity against drug-resistant bacteria. The company could receive up to $9.61 million more in additional funding if the project achieves certain development milestones, for a potential total of up to $12.17 million.
-
02.18.2020 | CARB-X funds Lytica Therapeutics to develop antibacterial peptides to treat drug-resistant infections in the lungs and other parts of the body
CARB-X is awarding Lytica Therapeutics, based in Cambridge, Massachusetts, USA, up to US$5.3 million in non-dilutive funding to develop antibacterial peptides with broad activity against multidrug-resistant bacteria.
-
02.04.2020 | CARB-X funds Pattern Bioscience to develop a new rapid diagnostic for drug-resistant bacterial infections
CARB-X is awarding Pattern Bioscience (formerly operating as Klaris Diagnostics), based in Austin, Texas, US, up to US$6.8 million in non-dilutive funding to develop a rapid identification and antimicrobial susceptibility test (ID/AST) to diagnose drug resistant infections quickly, and provide health professionals with vital information about which pathogen is causing the infection and which antibiotic is most likely to cure the infection.
-
01.13.2020 | CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them
CARB-X is awarding Trellis Bioscience, of Redwood City, California, USA, up to $3.2 million in non-dilutive funding, with the possibility of $3.8 million more if certain project milestones are met, to develop an innovative monoclonal antibody designed to disrupt the protective biofilm that makes bacteria resistant to antibiotics.
-
01.08.2020 | CARB-X funds TAXIS Pharmaceuticals to accelerate development of innovative efflux pump inhibitors (EPIs), a new drug class that would impair bacteria’s ability to fight antibiotics
CARB-X is awarding TAXIS Pharmaceuticals of Monmouth Junction, New Jersey, USA, up to US$3.2 million in non-dilutive funding to develop efflux pump inhibitors (EPI), a new drug class designed to destroy a major mechanism of multi-drug-resistant Pseudomonas aeruginosa bacteria. TAXIS is eligible for additional funding of up to $11.4 million if the project achieves certain milestones. TAXIS’ EPIs are designed to disable the bacteria’s efflux pumps, which act like bilge pumps to flush out antibiotics from the bacterial cell in order to safeguard the superbug from the effects of antibiotics.
-
01.07.2020 | CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria
CARB-X is awarding Centauri Therapeutics of Sandwich, UK, up to $1.4 million in non-dilutive funding to develop a novel dual-acting immunotherapy to treat serious infections caused by Gram-negative pathogens, including drug-resistant strains of Enterobacteriaceae, P. aeruginosa, and A.baumannii.
Toggle navigation